Sign Out
Pregnancy: The use of Meicoxia, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.
No clinical data on exposed pregnancies are available for Meicoxia. Studies in animals have shown reproductive toxicity. The potential for human risk in pregnancy is unknown. Meicoxia, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Meicoxia is contraindicated in pregnancy. If woman becomes pregnant during treatment, Meicoxia must be discontinued.
Lactation: It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use etoricoxib must not breast feed.
